{"name":"Eliem Therapeutics","slug":"eliem","ticker":"ELYM","exchange":"NASDAQ","domain":"eliemtx.com","description":"Eliem Therapeutics is a biopharmaceutical company focused on developing innovative treatments for neurological and oncological disorders. The company's pipeline includes several promising candidates, including ELYP001 and ELYP002, which are currently in clinical development. Eliem Therapeutics is well-positioned to capitalize on the growing demand for effective treatments in these therapeutic areas.","hq":"Redmond, WA, USA","founded":0,"employees":"","ceo":"Bob Bhatt","sector":"Neuroscience / Oncology Immunology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$95M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":46713000,"netIncome":-59851000,"cash":35685000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"ELYP001 patent cliff ($100M at risk)","drug":"ELYP001","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"ELYP002 patent cliff ($50M at risk)","drug":"ELYP002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ETX-018810","genericName":"ETX-018810","slug":"etx-018810","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ETX-018810","genericName":"ETX-018810","slug":"etx-018810","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Eliem Therapeutics Announces FDA Clearance of IND for ELYP001","summary":"Eliem Therapeutics received clearance from the FDA to initiate a Phase 2 clinical trial for ELYP001, a novel treatment for epilepsy.","drugName":"ELYP001","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Eliem Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Eliem Therapeutics reported revenue of $10.2 million and a net loss of $23.1 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1nbEU3c0JJcWpfMFRlR1lQTy1sZlRNTkJtTmxyczlVSHhXaE00dGI0dTVhMlp1TlFZRlYyYUR4enVsdjFka01NUXJZaDRJWTVia3VR?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ELYM Stock Price, News & Analysis - Stock Titan","headline":"ELYM Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZmVGbWY4VG1tX3Y1VGhkVUd2TnBScjJyODRMY3cxMzBoRUVqWVF2Y201dkJUdEpHTlQ0TXlHLU96ODhMT3JrS2dwSWdicGMtMk9zR290LVpFUnBCRk91ZGJMWFNLNGJPNDVDdGhKbUcwXzROVnZPWk9fSFlYTVJGX29EUFFlYUtLTzhqNmNDZzRra1RidXNuOERRNDFxWDl4bVVKVHRGLWhkVjVrc1p5X3dCa2UzeDZNMmV3?oc=5","date":"2024-10-03","type":"pipeline","source":"Fierce Pharma","summary":"Eliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffs - Fierce Pharma","headline":"Eliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPbXVWOHR5LUVkSjNzcXRFME9rZmY1YkJ0NFpmRVBEcjVDbWdLT2JIdDM1T0J3Wll3TVB1dl94VHFBVXZub0hCMlNhUGtjWG1yNWtKMFd1ZXlYMGFaaXdJSWZBRWU1ajFoUHVLUWlpXzJTU3d6cDVsZkI4YXllQTB6RlJldUJ4QmZUdkpJWDIzOThIUmY0WGNhYVNWXzBUcEhR?oc=5","date":"2024-09-23","type":"pipeline","source":"Seeking Alpha","summary":"Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha","headline":"Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNmN6Yno4aGEteTVfT0RMX3hYQ1hrLUlCLXZQWFhoeThtNG1pQjFCREVfekFNUWRKVkFTYmZXdWNSYU5jVl9ybFNqX0x6MVBXTVJ4am1FUG1MbDVrNG5hQVNKZ011QWRlUjhfRVhYdERsaF9lUzVwZi1xMUVib2lDeXVIU2tTMU1rY2xDMWVhSzBlQUloREZIaGI2NkFjTDBUaUlueThNUEF3REx2bmRvMFBYNlZrbGVaZTB6ZTEtSQ?oc=5","date":"2024-06-28","type":"pipeline","source":"Stock Titan","summary":"Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes - Stock Titan","headline":"Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1mazUwOGZ1bGY3WXdqMXJhQU1McEZ0b1c5V1NvMFZNMFY3TkhLbjFuSDh0V1FOc0UyaWE4RFJFWXI1dmdZUzlMUWc4NFNmeGppYVR1Z1NzUEhwUQ?oc=5","date":"2021-08-11","type":"pipeline","source":"MarketBeat","summary":"Eliem Therapeutics (ELYM) Stock Price, News & Analysis - MarketBeat","headline":"Eliem Therapeutics (ELYM) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5Mc2J1LWJ1RVEyMkVMalVSMF8zZkEwcjRENGNEbThVeWJSLUljQ0g2dm41c1lnd1dTU1FUMzgxcjNWUkZpN0hjME1iZ3B2QTN2Z0tpaWVpM1ZHOHY3REVoTzdn?oc=5","date":"2021-08-11","type":"pipeline","source":"MarketBeat","summary":"Eliem Therapeutics (ELYM) Stock Chart and Price History 2026 - MarketBeat","headline":"Eliem Therapeutics (ELYM) Stock Chart and Price History 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE45Y1hIOC15N25WYnVWeTFOQ01jeFY0ZXFYc2tNd1pjTmwtV094TGNfaHlnXzVjX2JIeFRWUUcwWmhYeklXeU1fcWhiRWJlUQ?oc=5","date":"2021-08-10","type":"pipeline","source":"Stock Titan","summary":"Latest ELYM News - Eliem Therapeutics Announces Rebranding and... - Stock Titan","headline":"Latest ELYM News - Eliem Therapeutics Announces Rebranding and...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOODRfNklFa0o3Rmw3SU9fUjlNXzBmZjRZcnJIWlhXOHVaWkRLbTZKUjdKVzRVVXVRd0ZVMy1jSjZmMFVsUVFfcHY2MXl5ME44S2YzQXJ6SHhHbzBsWmU4R2tOb092V3ZKUjJYaFYzUnE5VWRYaDZKRmpCTms0NFBXN0ZuSzE5VkN5WDh3YUR1N0hiM2U5aG9tbUNWQ1FoQkc5UUJSM3dZQXVic1k?oc=5","date":"2021-07-19","type":"pipeline","source":"GeekWire","summary":"Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public - GeekWire","headline":"Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public","sentiment":"neutral"}],"patents":[{"drugName":"ELYP001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":100000000},{"drugName":"ELYP002","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":50000000}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche Holding","Pfizer"],"therapeuticFocus":["Neurology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":46713000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-59851000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":35685000,"cashHistory":[],"totalAssets":167744000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}